Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

BACKGROUND: Signaling through VEGF/VEGFR induces cancer angiogenesis and affects immune cells. An increasing number of studies have recently focused on combining anti-VEGF/VEGFR agents and immune checkpoint inhibitors (ICIs) to treat cancer in preclinical and clinical settings. BD0801 is a humanized...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Liting, Gao, Xingyuan, Zhang, Haoyu, Tang, Jianxing, Wang, Qian, Li, Feng, Li, Xinxin, Yu, Xiaohong, Lu, Zhihong, Huang, Yue, Tang, Renhong, Yang, Wenqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539826/
https://www.ncbi.nlm.nih.gov/pubmed/34686154
http://dx.doi.org/10.1186/s12885-021-08859-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539826/
https://www.ncbi.nlm.nih.gov/pubmed/34686154
http://dx.doi.org/10.1186/s12885-021-08859-5

Ejemplares similares